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Fibrinogen-mimicking, multiarm nanovesicles 
for human thrombus-specific delivery of  
tissue plasminogen activator and targeted  
thrombolytic therapy
Yu Huang1†, Boram Gu1,2†, Isabelle I. Salles-Crawley3, Kirk A. Taylor4, Li Yu1, Jie Ren1,  
Xuhan Liu1, Michael Emerson4, Colin Longstaff5, Alun D. Hughes6,7, Simon A. Thom4,  
Xiao Yun Xu1*, Rongjun Chen1*
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its short circulation time 
and hemorrhagic side effects. Inspired by fibrinogen binding to activated platelets, we report a fibrinogen- 
mimicking, multiarm nanovesicle for thrombus-specific tPA delivery and targeted thrombolysis. This biomimetic 
system is based on the lipid nanovesicle coated with polyethylene glycol (PEG) terminally conjugated with a cyclic 
RGD (cRGD) peptide. Our experiments with human blood demonstrated its highly selective binding to activated 
platelets and efficient tPA release at a thrombus site under both static and physiological flow conditions. Its clot 
dissolution time in a microfluidic system was comparable to that of free tPA. Furthermore, we report a purpose- 
built computational model capable of simulating targeted thrombolysis of the tPA-loaded nanovesicle and with 
a potential in predicting the dynamics of thrombolysis in physiologically realistic scenarios. This combined experi-
mental and computational work presents a promising platform for development of thrombolytic nanomedicines.
INTRODUCTION
Intravascular administration of thrombolytic drugs for the treatment 
of cardiovascular diseases, such as acute myocardial infarction, 
ischemic stroke, and pulmonary embolism, has been shown to de-
crease both disability and mortality (1, 2). Tissue plasminogen acti-
vator (tPA), the only U.S. Food and Drug Administration–approved 
thrombolytic drug for acute ischemic stroke, can trigger the conver-
sion of plasminogen into plasmin (PLS), which, in turn, breaks up a 
thrombus via fibrinolysis (3, 4). However, direct intravenous infusion 
of tPA remains a major problem, since tPA can be easily inactivated 
by plasma components (e.g., plasminogen activator inhibitors) and 
removed by the liver, which results in a short circulation time (only 
2 to 6 min) and consequently diminishes its thrombolytic efficacy 
(5, 6). In addition, systemic off-target actions of tPA to catalyze cir-
culating plasminogen to PLS can cause a fatal hemorrhagic event 
even within the advised dose range (7, 8). To address these issues, a 
thrombus-targeted delivery system is required to encapsulate and 
protect tPA in the blood stream, specifically bind to a thrombus under 
flow conditions, and to efficiently trigger the release of tPA locally 
in a controlled manner, thereby improving thrombolytic efficacy and 
minimizing off-target side effects (9–12).
It has been well recognized that platelets play a vital role in the 
process of thrombosis and have been targeted for the treatment of 
cardiovascular diseases (13–15). In particular, activation of GPIIb-IIIa 
(IIb3) integrins (INTs) is a common pathway in platelet aggrega-
tion (16, 17). Normally, IIb3 INTs are inactive on the surface of 
circulating platelets. In the event of thrombus formation after vas-
cular injury, platelets will be in an active state, with IIb3 INTs 
abundantly expressed and activated with a conformational change 
on their surface. This conformational change of IIb3 allows specific 
binding of activated platelets to the main ligand of fibrinogen through 
the arginine-glycine-aspartic acid (RGD) motifs located in each of its two 
A chains (18). The resulting “bridging effect” causes platelet aggre-
gation (Fig. 1A) (19, 20). In this context, activated platelets comprise 
ideal receptors for selective delivery of thrombolytic drugs to a thrombus, 
because the aggregation of activated platelets and expression of abun-
dant active IIb3 INTs on the activated platelet surface (40,000 to 
80,000 copies per platelet) are critical events in thrombosis (21–23).
Several thrombus-targeted tPA delivery systems have been designed 
through the use of fibrinogen-derived peptides (9). For example, 
Chung et al. (24) encapsulated tPA into poly-(lactide-coglycolide) 
nanoparticles, which were coated with the Gly-Arg-Gly-Asp peptide–
conjugated chitosan, to enhance thrombolysis in a blood clot–
occluded tube model. Absar et al. (25) reported an albumin- camouflaged 
construct for thrombus-specific delivery of tPA in a rat thrombus 
model through thrombin-cleavable chemical conjugation of tPA 
onto human serum albumin decorated with a homing peptide 
(CQQHHLGGAKQAGDV). However, these approaches suffered 
from either a major challenge to realize triggered release of tPA spe-
cifically at a thrombus site or a reduction of tPA biological activity 
due to direct chemical conjugation (12). Recently, we developed an 
activated platelet–sensitive nanoliposomal tPA delivery system, which 
was PEGylated and coated with a cyclic RGD (cRGD) peptide 
cyclo(Arg-Gly-Asp-D-Phe-Val), to achieve selective and efficient 
thrombolysis in a sheep blood clot model under a static condition 
(26). The cRGD peptide was demonstrated to induce membrane fu-
sion upon selective binding of the liposomes to activated platelets, 
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Fig. 1. Schematic illustrations of platelet aggregation, thrombus formation and targeted thrombolysis, and the computational model under flow conditions. 
(A) Schematic illustration of the mechanism of platelet aggregation through the “bridging effect” between fibrinogen and activated platelets. (B) Schematic illustration 
of a fibrinogen-mimicking, multiarm lipid nanovesicle, which is denoted as tPA-cRGD-PEG-NV. (C) Schematic illustration of thrombus formation and targeted thromboly-
sis through tPA-cRGD-PEG-NV mediated thrombus-specific delivery and triggered release of tPA. (D) The computational model under flow conditions, which consists of 
a rectangular channel with initial thrombi artificially created at three locations (clots 1 to 3). The height (0.1 mm) and width (0.4 mm) of the channel match the microflu-
idics model in our experiment. The length (3.5 mm) is arbitrarily chosen, since the actual microfluidics channel (280 mm in length) is excessively long compared to its 
height. The volumes of clots 1, 2, and 3 are 4.5 × 10−3, 7.2 × 10−3, and 4.5 × 10−3 mm3, respectively. (E) A schematic diagram of reactions taking place in the plasma and 
within a thrombus. PLG, plasminogen; PLS, plasmin; AP, 2–anti-PLS; MG, 2-macroglobulin; FBG, fibrinogen; FDP, fibrin degradation product; PAI, plasminogen activator 
inhibitor-1; PLT, activated platelets; INTs, IIb3 integrins; F, fibrin fiber binding sites; ND, nanodrug of tPA-cRGD-PEG-NV. Black dashed lines denote reaction kinetics and 
can describe either a reversible or irreversible reaction depending on the arrow type. Blue dashed arrows represent enzymatic action in a conversion reaction. Red dashed 
arrows indicate inactivation of a pointed species by a pointing species, i.e., AP and MG inactivate PLS, while PAI inhibits tPA. FBG is included in the model as its low level 
in the plasma indicates a risk of bleeding.
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leading to triggered release of tPA selectively at a clot site. Although 
this strategy is considered to be a notable advancement toward 
localized thrombolysis, the thrombolytic process remains to be validated 
in a real human blood clot model, especially under physiological flow 
conditions. Furthermore, there is a need to gain mechanistic under-
standing of the complex interplay among multiple physical and bio-
chemical processes that take place in thrombolysis with the new 
targeted tPA delivery system. This can only be achieved by combining 
computational modeling with purpose-designed experiments. Once 
fully validated, the computational model can be further used to op-
timize the delivery mode and dose regimen in future animal studies 
and human trials.
Here, inspired by the “bridging effect” between fibrinogen and 
activated platelets at a thrombus site, we first report this fibrinogen- 
mimicking, multiarm nanovesicle (Fig. 1, B and C) for thrombus- 
specific delivery of tPA and targeted thrombolysis in human blood 
clot models under static and physiological flow conditions via a 
combination of experimental and computational work. The self- 
assembled lipid nanovesicle is PEGylated to improve stability, and 
its hydrophilic cavity enables efficient encapsulation of tPA. The 
terminals of PEG arms are decorated with cRGD peptides with 
conformational restriction. These cRGD peptides have been reported 
to display a very high specificity and affinity for IIb3 INTs abun-
dantly expressed on the activated platelet surface at a clot site in 
contrast with other RGD-binding INTs such as v3 and 51 found 
in tumor, endothelial, and stromal cells (27, 28). This tPA-loaded, 
cRGD-decorated, PEGylated lipid nanovesicle (denoted as tPA-cRGD- 
PEG-NV) is a fibrinogen-mimicking nanovesicle containing many 
thrombus-targeted cRGD-PEG arms. In the present work, human 
blood was used to confirm the specific binding of tPA-cRGD-PEG-
NV to activated platelets in vitro and its thrombus selectivity under 
physiological flow conditions in a microfluidic system. Controlled 
tPA release triggered by activated platelets was demonstrated, the 
cRGD-PEG arm density was optimized, and the tPA release mech-
anism was further elucidated in the human blood clot model. Effi-
cient and selective fibrinolysis and thrombolysis under both static 
and physiological flow conditions were achieved. Furthermore, in 
parallel with the experimental work, we developed a computational 
model to mimic the activated platelet–triggered tPA release behavior 
and demonstrated the capability of the model to simulate targeted 
thrombolysis of tPA-cRGD-PEG-NV under the same experimental 
conditions (Fig. 1, D and E) (29–31). Our combined experimental 
and computational results suggest that this biomimetic tPA-cRGD-
PEG-NV system is a promising platform for targeted thrombolytic 
therapy with minimal systemic tPA exposure. In the future, the validated 
computational model can be used to predict the efficacy of the tPA-




The fibrinogen-mimicking, multiarm nanovesicles tPA-cRGD-
PEG-NVs were constructed by lipid film hydration and extruded 
through 200-nm polycarbonate membranes as reported in our pre-
vious work and illustrated in Fig. 2A for completeness (26). The 
tPA-loaded nanovesicles without any surface modification (denoted 
as tPA-NVs) and the tPA-loaded nanovesicles surface modified by 
PEG only (denoted as tPA-PEG-NVs) were fabricated for comparison. 
Hydrodynamic diameters and polydispersity index (PDI) of the 
nanovesicles were determined by dynamic light scattering (DLS). 
As shown in fig. S1, the diameter of tPA-cRGD-PEG-NV was 
165.3 ± 4.1 nm (PDI = 0.101 ± 0.014), which was slightly larger than 
that of tPA-PEG-NV (161.1 ± 5.2 nm; PDI = 0.108 ± 0.016) and 
tPA-NV (151.7 ± 3.4 nm; PDI = 0.113 ± 0.021), suggesting success-
ful surface modification of the nanovesicles with cRGD-PEG arms. 
The morphology of tPA-cRGD-PEG-NV was shown by transmission 
electron microscope (TEM) to be spherical, and the TEM particle 
size was consistent with the DLS size (Fig. 2B). Figure S2A shows that 
tPA-cRGD-PEG-NV had an encapsulation efficiency of 31.4 ± 3.3%, 
slightly higher than tPA-NV (28.6 ± 3.8%) and tPA-PEG-NV 
(30.1 ± 2.5%). As displayed in Fig. 2C, the zeta potential of tPA-
cRGD-PEG-NV (−41.7 ± 2.1 mV) was comparable to that of tPA-
NV (−35.4 ± 1.9 mV) and tPA-PEG-NV (−42.3 ± 1.3 mV). Stability 
of the tPA-loaded nanovesicles was investigated by detecting the parti-
cle size change and drug leakage during storage at 4°C. As shown in 
Fig. 2D and fig. S2B, negligible changes in particle size or drug leak-
age were observed for tPA-PEG-NV and tPA-cRGD-PEG-NV after 
30 days of storage. By contrast, tPA-NV showed a considerable 
diameter increase to more than 400 nm and caused tPA leakage as 
high as ~50% during storage. This is in good agreement with the 
previous finding that surface coating of the nanovesicles with PEG 
or cRGD-PEG significantly enhances stability (26).
Selective binding to human activated platelets
To investigate whether the cRGD peptide could improve the selec-
tivity of tPA-cRGD-PEG-NV binding to human activated platelets, 
we first examined the binding behavior of the nanovesicles containing 
the fluorescein isothiocyanate (FITC)–labeled tPA using confocal 
laser scanning microscopy (CLSM). As shown in Fig. 2 (E and F), 
both tPA-PEG-NV and tPA-cRGD-PEG-NV caused negligible 
staining of human resting platelets. By contrast, tPA-cRGD-PEG-
NV exhibited remarkably enhanced attachment to human activated 
platelets as compared to tPA-PEG-NV (Fig. 2, G and H). Quantitative 
analysis of the FITC fluorescence intensity in CLSM images suggested 
that the selective binding of tPA-cRGD-PEG-NV to human activated 
platelets was about five times higher than tPA-PEG-NV (Fig. 2I). 
Flow cytometry analysis, as shown in fig. S3 and Fig. 2J, further con-
firmed that tPA-PEG-NV only displayed marginal binding to both 
resting and activated platelets, while tPA-cRGD-PEG-NV demon-
strated a very high selectivity to activated platelets. These results 
consolidate that cRGD peptide arms on the surface of nanovesicles 
can efficiently enhance specific targeting to human activated platelets 
at a blood clot site. Furthermore, the amount of cRGD arms present 
on the terminal of cRGD-PEG-DSPE could be controlled to maxi-
mize the binding affinity. As shown in Fig. 2K, there was a sharp 
increase in the binding affinity of tPA-cRGD-PEG-NV to human 
activated platelets when the cRGD arm density increased from 
1.8 × 104 to 9.0 × 104 arms per vesicle, beyond which the influence 
of cRGD arm coating density was insignificant. This suggests that 
9.0 × 104 cRGD-PEG-DSPE per vesicle is an important threshold 
value to achieve maximal targeting to human activated platelets.
Thrombus selectivity under physiological flow conditions
The specific targeting ability of tPA-cRGD-PEG-NV to human blood 
clots under physiological flow conditions was investigated in a 
microfluidics system, as shown in Fig. 3A. The nonocclusive human 
thrombi were first formed in the biochip (Fig. 3B) and monitored by 
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fluorescence microscopy. Briefly, citrated human blood was per-
fused in the collagen-coated biochip channel at a shear rate of 1000 
s−1 to form nonocclusive thrombi (fig. S4, A and B). Then, the chan-
nels were washed by perfusion with Hepes-Tyrode’s (HT) buffer for 
2 min. After that, the FITC-labeled tPA-cRGD-PEG-NV were 
perfused in the thrombi-containing channels to investigate its selec-
tive targeting. The FITC-labeled tPA-PEG-NV without cRGD arms 
were used as the control. As shown in Fig. 3C, human thrombi were 
visualized under the bright field, but negligible thrombus-specific 
green fluorescence was observed after perfusion with tPA-PEG-NV. 
Fig. 2. Preparation, characterization, and selective binding of tPA-cRGD-PEG-NV. (A) Schematic representation of the preparation process of tPA-cRGD-PEG-NV. 
(B) Typical DLS plot of tPA-cRGD-PEG-NV in PBS buffer (pH 7.4). Inset: representative TEM image of tPA-cRGD-PEG-NV. Scale bar, 100 nm. (C) Zeta potential of tPA-NV, 
tPA-PEG-NV, and tPA-cRGD-PEG-NV. (D) Particle size change of tPA-NV, tPA-PEG-NV, and tPA-cRGD-PEG-NV after storage at 4°C for 30 days. CLSM images of human resting 
platelets incubated with the FITC-labeled (E) tPA-PEG-NV and (F) tPA-cRGD-PEG-NV. CLSM images of human activated platelets incubated with the FITC-labeled (G) tPA-
PEG-NV and (H) tPA-cRGD-PEG-NV. (I) Mean fluorescence intensity of FITC in the CLSM images of human resting and activated platelets after incubation with the FITC- 
labeled tPA-PEG-NV and tPA-cRGD-PEG-NV, respectively, as analyzed by ImageJ. (J) Relative fluorescence intensity of human resting and activated platelets treated with 
the FITC-labeled tPA-PEG-NV and tPA-cRGD-PEG-NV, respectively, as measured by flow cytometry. (K) Relative fluorescence intensity of human activated platelets incu-
bated with the FITC-labeled tPA-cRGD-PEG-NV containing different cRGD arm densities, as measured by flow cytometry. Data are presented as the average ± SD (n = 3). 
Statistical analysis for Fig. 2 (C and D) was performed using the analysis of variance (ANOVA) (multiple comparisons) test, while the Student’s t test for Fig. 2 (I and J). 
*P < 0.05, **P < 0.01, and ****P < 0.0001, respectively.
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By comparison, the green fluorescently labeled tPA-cRGD-PEG-NV 
efficiently and specifically bound to human thrombi. Quantitative 
analysis of the FITC fluorescence intensity showed that the specific 
targeting of tPA-cRGD-PEG-NV to human blood clots under 
physiological flow conditions was markedly improved as compared 
to tPA-PEG-NV without cRGD arms (Fig. 3D). One potential lim-
itation of nanovesicles targeting activated platelets for thrombolysis 
is the possibility that the peptide arms on the nanovesicles may have 
impact on platelet aggregation in the circulating platelet population. 
To assess this effect, human platelets were preincubated with cRGD-
PEG-NV (lipid concentration of 10 M) before stimulation by the 
platelet agonist (thrombin). As shown in fig. S4C, the platelet aggre-
gation was thrombin concentration responsive for the nanocarriers, 
and thrombin (1 U ml−1) was an important threshold value to 
achieve maximal platelet aggregation. The data in fig. S4 (D and E) 
demonstrated that the nanocarriers did not significantly alter the ex-
tent of human platelet aggregation (88.10 ± 1.26%) as compared with 
the agonist-only group (86.43 ± 0.25%).
Triggered tPA release and release mechanisms
After selective targeting to a human thrombus, efficient release of 
tPA from tPA-cRGD-PEG-NV locally at the clot site is crucial for 
effective thrombolysis. Figure 4A shows that the presence of human 
activated platelets enabled the release of 83.6 ± 3.2% of tPA from 
tPA-cRGD-PEG-NV within 1.5 hours, considerably higher than the 
tPA release (29.7 ± 3.9%) from tPA-PEG-NV without cRGD arms. 
It is worth pointing out that incubation of human resting platelets 
with tPA-cRGD-PEG-NV led to only 5.0 ± 3.1% tPA release. Those 
results suggest that the release of tPA from the fibrinogen-mimicking, 
multiarm lipid nanovesicles was triggered by their specific interac-
tions with human activated platelets as a result of selective binding 
of cRGD arms to IIb3 INTs, which was further validated by the 
platelet concentration–dependent tPA release shown in Fig. 4B.
It was reported in our previous work that the drug-loaded lipo-
somes containing surface coating of cRGD demonstrated selective 
binding to sheep activated platelets under a static condition, which 
resulted in efficient drug release via lipid membrane destabilization 
involving membrane fusion between liposomes and sheep activated 
platelets (26). Here, calcein dequenching and fluorescence resonance 
energy transfer (FRET) assays (26, 32, 33) were carried out to vali-
date that the fibrinogen-mimicking, multiarm lipid nanovesicles follow 
the same drug release mechanism in a human blood clot model. As 
shown in Fig. 4C, after incubation of the calcein-carrying cRGD-
PEG-NV with phosphate-buffered saline (PBS) buffer (pH 7.4) only 
or human resting platelets, calcein remained self-quenched in the 
nanovesicles, and no significant variations in relative calcein fluo-
rescence intensity were detected. In comparison, the presence of 
human activated platelets rapidly triggered an efficient calcein release 
as a result of the cRGD-PEG-NV membrane disruption, leading to 
significantly enhanced calcein fluorescence intensity. Note that inhibition 
Fig. 3. Microfluidics system and thrombus selectivity under physiological flow conditions. (A) The microfluidics system setup. i to iv: Vena 8 Fluro+ biochip, micro-
pump, fluorescence microscope, and circulation flow. (B) Schematic illustration of a human blood clot in the biochip. (C) Representative bright-field and fluorescence 
images of human blood clots in the flow chamber after perfusion with the FITC-labeled tPA-PEG-NV and tPA-cRGD-PEG-NV, respectively. (D) FITC fluorescence intensity 
in the fluorescence images of human thrombi after incubation with the FITC-labeled tPA-PEG-NV and tPA-cRGD-PEG-NV, respectively. Data are presented as the average ± SD 
(n ≥ 3). Statistical analysis was performed using the Student’s t test. *P < 0.05. Photo credit: Yu Huang, Imperial College London.
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of IIb3 INTs present on the human activated platelet surface with 
eptifibatide reversed the relative calcein fluorescence intensity to a 
level comparable to that achieved by the calcein-carrying cRGD-
PEG-NV in the presence of PBS buffer only or human resting plate-
lets. This confirms that the vesicle membrane disruption and 
consequent payload release is facilitated by the specific interaction 
between cRGD multiarms on the nanovesicle surface and IIb3 INTs 
on the human activated platelet surface. Furthermore, the FRET 
donor 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD) and acceptor 
rhodamine (Rhod) were coated onto the cRGD-PEG-NV surface. 
Figure 4D shows that the NBD fluorescence was enhanced rapidly 
and considerably upon incubation of the fibrinogen-mimicking, 
multiarm lipid nanovesicles with human activated platelets. This 
was attributed to the decreased surface density of the donor 
NBD and the increased distance between the donor NBD and the 
acceptor Rhod, resulting from the fusion between the lipid mem-
brane and the human activated platelet membrane (26, 34–36). By 
contrast, incubation with PBS or human resting platelets caused 
minimal membrane fusion and a consequently negligible increase 
in the NBD fluorescence. This membrane fusion was induced by 
specific interaction between cRGD peptide arms and IIb3 INTs, 
and it was confirmed that inhibition of IIb3 INTs on human acti-
vated platelets with eptifibatide caused a negligible increase in the 
NBD fluorescence.
Targeted fibrinolysis and thrombolysis under  
static conditions
The targeted fibrinolytic activity of tPA-cRGD-PEG-NV was 
evaluated by a human fibrin plate assay (Fig. 5A). As shown in 
Fig. 5 (B and C), no obvious fibrin lysis was observed after treat-
ment of human fibrin clots with PBS buffer (pH 7.4). However, 
treatment with tPA-cRGD-PEG-NV led to a clear fibrin lysis zone 
(2.13 ± 0.19  cm2), which is comparable to that with free tPA 
(2.24 ± 0.15 cm2), demonstrating effective fibrinolysis resulting 
from the human activated platelet–triggered tPA release from tPA-
cRGD-PEG-NV. The area of fibrin lysis zone induced by tPA-PEG-
NV without cRGD arms (0.86 ± 0.32 cm2) was significantly smaller.
Furthermore, the targeted thrombolytic activity of tPA-cRGD-
PEG-NV under static conditions was examined by a halo human blood 
clot assay as illustrated in Fig. 5D. Briefly, halo-shaped human blood 
clots with an empty center were treated with different tPA formula-
tions, and the extent of clot dissolution was monitored via mea-
surement of absorbance due to the release of red blood cells upon 
thrombolysis (37–39). As visualized in Fig. 5E, the halo-shaped 
human blood clots were dissolved completely by free tPA or tPA-
cRGD-PEG-NV after 1 hour of treatment at 37°C. By contrast, the 
remaining human blood clots were clearly visible after treatment with 
tPA-PEG-NV or PBS buffer (pH 7.4) only. Figure 5F shows that the 
thrombolytic activity of empty vesicles without tPA encapsulation 
Fig. 4. Triggered drug release and release mechanisms. (A) tPA release profiles of tPA-PEG-NV and tPA-cRGD-PEG-NV after incubation with human resting or activated 
platelets (1.0 × 108/ml). (B) tPA release profiles of tPA-cRGD-PEG-NV after incubation with different concentrations of human activated platelets for 2 hours. (C) Real-time 
monitoring of the relative calcein fluorescence intensity after incubation of the calcein-carrying cRGD-PEG-NV (self-quenching concentration of calcein at 50 mM) with 
PBS buffer only, human resting platelets, human activated platelets, and eptifibatide-pretreated human activated platelets, respectively. (D) Real-time monitoring of the 
NBD fluorescence intensity of after incubation of the NBD [1 mole percent (mol %)]– and Rhod (1 mol %)–coated cRGD-PEG-NV with PBS buffer only, human resting 
platelets, human activated platelets, and eptifibatide-pretreated human activated platelets, respectively. Data are presented as the average ± SD (n = 3).
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Fig. 5. Targeted fibrinolysis and thrombolysis under static conditions. (A) Schematic illustration of the human fibrin clot model and the fibrin lysis zone induced by 
tPA-cRGD-PEG-NV. (B) Representative photograph of human fibrin clots and (C) calculated area of human fibrin lysis zone after treatment with PBS buffer (pH 7.4) only, 
tPA-PEG-NV, tPA-cRGD-PEG-NV and free tPA, respectively, which were preincubated with human activated platelets at 37°C for 2 hours. (D) Schematic illustration of the 
halo human blood clot assay protocol. (E) Representative photograph of human blood clots treated with PBS buffer (pH 7.4) only, tPA-PEG-NV, tPA-cRGD-PEG-NV, and 
free tPA, respectively, at 37°C for 1 hour. (F) Time-dependent clot lysis in the halo human blood clot model after treatment with PBS buffer (pH 7.4) only, PEG-NV, cRGD-
PEG-NV, tPA-PEG-NV, tPA-cRGD-PEG-NV, and free tPA at 37°C for 1 hour, respectively. Data are presented as the average ± SD (n = 3). Statistical analysis was performed 
using the ANOVA (multiple comparisons) test. ***P < 0.001, and NS represents no significant difference between two groups.
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(i.e., cRGD-PEG-NV and PEG-NV) was as negligible as that of PBS 
buffer (pH 7.4) only, suggesting that the components of the vesicles 
did not contribute to the human blood clot dissolution. Human 
blood clot lysis induced by tPA-cRGD-PEG-NV initially lagged be-
hind that achieved by free tPA. This could be attributed to the gradual 
time-dependent release of tPA from the fibrinogen-mimicking ves-
icles as shown in Fig. 4A. With extending treatment time to 60 min, 
tPA-cRGD-PEG-NV and free tPA displayed a comparable ability to 
completely dissolve human blood clots. For comparison, the extent 
of human blood clot lysis was shown to be only ~50% after treat-
ment with tPA-PEG-NV without cRGD arms for 60 min under the 
same static conditions.
Computational simulation of tPA release and blood clot lysis 
under static conditions
Our purpose-built computational model for the targeted thrombo-
lytic nanovesicle was first used to simulate the release of tPA trig-
gered by activated platelets (Fig. 6A). The model parameters describing 
the leakage and triggered release of our nanodrug (ND), tPA-cRGD- 
PEG-NV (denoted as ND for simplicity when describing the com-
putational model), were determined by fitting the simulation results 
to the experimental data obtained under static conditions in the 
absence of human blood clots [data shown in Fig. 4 (A and B)]. By 
using these experimental data obtained under well-controlled 
conditions, it was possible to derive the essential model parameters 
for the developed ND. The stochiometric coefficient rel in Eqs. 8 
and 10 (presented in Materials and Methods) was set to be 3570 based 
on the nanoparticle tracking analysis (NTA) of the average molar 
ratio between tPA and ND (fig. S5). The initial concentration of ND 
was arbitrarily chosen, as it would not affect the amount of tPA re-
leased relative to the initial amount of tPA loaded in the ND. As 
shown in Fig. 6B, the experimental data of tPA release in the presence 
of human resting and activated platelets, respectively (as presented 
in Fig. 4A), were compared with the model predictions. Using the 
experimental data of tPA release in the presence of resting platelets 
alone (red triangles in Fig. 6B), the leakage rate constant, Kleak, was 
estimated to be 2.946 × 10−9 s−1. Temporal tPA release at a concen-
tration of 1 × 108 activated platelets/ml (blue squares in Fig. 6B) was 
used to estimate the rate constants of binding and unbinding be-
tween ND, the INTs, ka,ND and kd,ND, and the release rate constant 
krel. Details can be found in the Supplementary Materials. The val-
ues for these parameters were as follows: ka,ND = 2.622 × 10−2 M−1 s−1, 
kd,ND = 7.516 × 10−3 s−1, and krel = 0.1098 s−1. It is worth noting that 
the binding rate of ND to activated platelets (ka,ND) was approxi-
mately 26 times faster than that of tPA to fibrin, reflecting the much 
higher targeting efficiency of ND to activated platelets than tPA to 
fibrin. Using the estimated parameters, the amount of tPA released 
at different concentrations of activated platelets was predicted. As 
Fig. 6. Computational simulation results under static conditions. (A) Schematic illustration of activated platelet-triggered tPA release specifically at a thrombus site 
using the fibrinogen-mimicking, multiarm ND. (B) Comparison of tPA release from the ND between model predictions and experiments with human resting and activated 
platelets at 1 × 108/ml. (C) Comparison of tPA release from the ND between model predictions and experiments at different concentrations of human activated platelets 
after incubation for 2 hours. Experiment data are presented as the average ± SD (n = 3). Statistical analysis for experiment data was performed using the ANOVA (multiple 
comparisons) test. **P < 0.01 and ****P < 0.0001, respectively. (D) Predictions of time- dependent tPA release from the ND at different concentrations of human activated 
platelets. Numbers on each curve indicate the concentrations of human activated platelets in (×104/ml).
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shown in Fig. 6C, a good agreement was achieved between the model 
predictions and experimental measurements for a wide range of 
activated platelet concentrations. Figure 6D shows that, within the 
120-min time window, the tPA release profile was almost linear at 
low concentrations of activated platelets, and the percentage of tPA 
release increased with the number of activated platelets. The tPA 
release profile at high concentrations of activated platelets was dif-
ferent, which showed a sharp increase in the initial phase and reached 
its peak more rapidly than at low levels of activated platelets.
The halo human blood clot lysis experiment was then simulated 
by including all the fibrinolytic and plasma reactions in addition to 
the activated platelet–triggered tPA release mechanism (details can 
be found in table S3). As depicted in fig. S9, the simulated blood clot 
lysis by free tPA closely matched the experimental data. Our simu-
lation results for the ND, however, showed much faster clot lysis 
than the experimental results. There are two possible explanations. 
First, blood clot lysis was measured differently in the computational 
model calculations and experiment. The computational model di-
rectly calculated the extent of lysis of fibrin fibers, whereas, in the 
experiment, the extent of clot lysis was determined by monitoring 
the amount of red blood cells escaped from a disintegrated fibrin 
fiber network following fibrinolysis. There was likely a time lag be-
tween the dissolution of the fibrin fiber network and the arrival of 
red blood cells at the measuring point. It was also likely that there 
existed greater hindrance effects on moving red blood cells due to 
higher population density in the well where the ND was added com-
pared to only free tPA in the well. Second, the static model simulated 
blood clot lysis under the assumption of a perfectly mixed system, 
which led to an overestimation of ND concentration on the surface 
and inside the blood clot. In reality, upon addition of the ND, it would 
slowly travel toward the blood clot surface and penetrate the clot in 
the absence of forced convective transport. In addition, the diffusive 
transport rate of the ND was much slower than that of tPA due to its 
larger size. According to the Stokes-Einstein equation, diffusivity of 
a molecule in an ideal condition is inversely proportional to its radius 
(40). Therefore, the diffusive transport of tPA, the ND, and red blood 
cells should be included in the computational model to reproduce 
the halo thrombolysis experimental results. This led to further im-
provement of the computational model by incorporating both the 
diffusive and convective transport of tPA, the ND, and other plasma 
proteins.
Targeted thrombolysis under flow conditions
The targeted, efficient fibrinolytic and thrombolytic ability of tPA-
cRGD-PEG-NV under static conditions prompted us to examine its 
targeted thrombolysis under physiological flow conditions in a 
microfluidics system (41, 42). As shown in fig. S6A, citrated human blood 
was preincubated with 3,3′-dihexyloxacarbocyanine iodide (DIOC6) 
and Alexa Fluor 647–conjugated fibrinogen (FBG) (AF-647-FBG) 
and was then perfused in the collagen- and tissue factor (TF)–coated 
channels at a shear rate of 1000 s−1. As shown in fig. S6B, the accu-
mulation of platelet-associated green fluorescence and fibrin-associated 
red fluorescence was observed after perfusion for only 2 min. Ex-
tension of perfusion time up to 8 min enhanced both green (platelet) 
and red (fibrin) fluorescence, suggesting that stable nonocclusive human 
thrombi were formed. Subsequently, the channels were washed by 
perfusion with HT buffer and then perfused with recalcified human 
blood containing cRGD-PEG-NV, tPA-PEG-NV, tPA-cRGD-PEG-
NV, or free tPA at 1000 s−1 for the indicated time durations. The 
real-time changes in the green (platelet) and red (fibrin) fluorescence 
were monitored. As shown in Fig. 7 (A and D) and fig. S7, during 
the perfusion with cRGD-PEG-NV (blank vesicles) for 12 min, there 
was only a negligible decrease in both fibrin and platelet fluorescence, 
suggesting no obvious thrombolysis (movie S1). Upon perfusion 
with tPA-PEG-NV without cRGD peptide arms, a slight decrease in the 
fibrin and platelet fluorescence was observed over time (Fig. 7, B and D; 
fig. S7; and movie S2). By contrast, the fluorescence of fibrin and 
platelets completely disappeared under perfusion with the fibrinogen- 
mimicking, multiarm vesicles tPA-cRGD-PEG-NV over 12 min, 
indicative of complete clot dissolution and removal (Fig. 7, C and D; 
fig. S7; and movie S3), which was similar to perfusion with free tPA 
(fig. S8 and movie S4). Note that under perfusion with tPA-cRGD-
PEG-NV, the fibrin fluorescence started to decrease (~2 min) earlier 
than the platelet fluorescence (~5 min). This time difference vali-
dates that fast release of tPA from the vesicles locally at a blood clot 
site initially resulted in fibrin lysis that, in turn, destabilized platelet 
aggregates and consequently facilitated complete clot removal (43). 
As shown in Fig. 7E, the time required for complete human blood 
clot removal after perfusion with tPA-cRGD-PEG-NV (9.73 ± 0.65 min) 
was comparable with free tPA (8.34 ± 1.19 min), while perfusion 
with tPA-PEG-NV without cRGD arms led to a decrease in fibrin 
fluorescence by only ~20% (Fig. 7D) under the same conditions. The 
considerably shorter time for complete human blood clot removal 
by tPA-cRGD-PEG-NV was attributed to its specific targeting to 
thrombi and consequently much more efficient and faster release of 
tPA at the human blood clot site as compared to tPA-PEG-NV 
without cRGD arms (no significant clot removal during 12 min).
Computational simulation of targeted thrombolysis under 
flow conditions
Using the improved computational model accounting for the diffu-
sive and convective transport of tPA, the ND, and other plasma 
proteins, simulations of targeted thrombolysis of our ND under 
continuous flow in a rectangular channel were performed as illus-
trated in Fig. 1D. Six scenarios were simulated by varying the thrombus 
volume (small or large), composition (coarse or dense), and the type 
of drug (free tPA or the ND). A small thrombus scenario was simu-
lated by considering clot 2 (shown in Fig. 1D) alone, while a large 
thrombus scenario involved all three clots, clots 1 to 3. The coarse 
and dense thrombus scenarios were simulated by varying the volume 
fraction of activated platelets in the clot (p = 0.01 and 0.05) for a 
fixed volume fraction of the fibrin fiber network (f = 0.001) (44, 45). 
In other words, the dense thrombus simulated here represented a 
platelet-rich thrombus. These values were within the range found in 
the literature (44, 45). The inlet velocity was calculated on the basis 
of the experimental conditions in the microfluidics system (40 l min−1 
and the cross-sectional area of the rectangular channel). As the dif-
fusivity of ND is unknown, it was assumed to be half of the diffusivity 
of free tPA because of its larger size. Initial and boundary conditions 
for velocity, pressure, and concentrations of all the species and addi-
tional model parameters can be found in the “Flow symmetry” section 
of the Supplementary Materials. Our simulation results demonstrated 
that complete thrombolysis was achieved at 263 s (tPA) and 779 s 
(ND) for the small coarse thrombi, 334 s (tPA) and 327 s (ND) for 
the small dense thrombi, and 334 s (tPA) and 329 s (ND) for the 
large dense thrombi.
In the dense thrombus scenarios, the lysis completion time for 
tPA and the ND was comparable, which is consistent with the 
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Fig. 7. Targeted thrombolysis under flow conditions. Recalcified citrated blood labeled with DIOC6 and AF-647-FBG was perfused in the collagen- and TF-coated 
channels for 8 min at a shear rate of 1000 s−1. Channels were washed with HT buffer for 2 min, and then the recalcified blood containing (A) cRGD-PEG-NV, (B) tPA-PEG-NV, 
and (C) tPA-cRGD-PEG-NV, respectively, at an equivalent tPA concentration of 15 g ml−1 was perfused in the thrombi-containing channels for the indicated time dura-
tions at a shear rate of 1000 s−1. The representative fluorescence images of platelets (green) and fibrin (red) at human thrombi were collected at different perfusion times. 
(D) Real-time changes in the red fluorescence of fibrin at human thrombi after perfusion with cRGD-PEG-NV, tPA-PEG-NV, and tPA-cRGD-PEG-NV, respectively. (E) Time 
required for complete human blood clot removal after perfusion with tPA-PEG-NV, tPA-cRGD-PEG-NV, and free tPA, respectively. Data are presented as the average ± SD 
(n ≥ 3). Statistical analysis was performed using the ANOVA (multiple comparisons) test. *P < 0.05 and **P < 0.01, respectively.
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Fig. 8. Simulation results for targeted thrombolysis under flow conditions. (A) to (D) are the results for all six scenarios with varying thrombus size, platelet density, 
and drug type [blue dashed line, small coarse thrombi with free tPA (S-C + tPA); orange dashed line, small coarse thrombi with the ND (S-C + ND); blue solid line, small 
dense thrombi with free tPA (S-D + tPA); orange solid line, small dense thrombi with the ND (S-D + ND); blue dotted line, large dense thrombi with free tPA (L-D + tPA); 
orange dotted line, large dense thrombi with the ND (L-D + ND)]. In (A) to (D), results for the small and large dense thrombi are indistinguishable. (A) Real-time changes 
in the extent of thrombolysis. (B) Real-time changes in the fibrin volume fraction. (C) Real-time changes in the concentration of fibrin-bound tPA. (D) Real-time changes 
in the concentration of fibrin-bound PLS. (E to G) Large dense thrombi treated with the ND. (E) Local extent of thrombolysis and flow velocity at different times for the 
case of large dense thrombi with the ND. (F) Temporal concentrations of tPA in the plasma phase (CtPA), fibrin-bound tPA (ntPA), fibrin-bound PLS (nPLS), and encapsulated 
tPA in the ND (CND-tPA). (G) Temporal concentrations of the ND loaded with tPA (CND), the empty ND (CND,empty), INT-bound ND (CINT-ND), and INT-bound empty ND 
(CINT-ND,empty). Each variable displayed in (A) to (D), (F), and (G) represents its average value over the clot volume.
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experimental results. Although a direct comparison of the lysis com-
pletion time between the simulation and experiment could not be made 
as the initial conditions of experimental thrombi were unknown, the 
lysis completion time with the ND recorded in the experiment 
(9.73 ± 0.65 min) was within the range (5.45 to 12.98 min) predicted 
by the computational model. Previous studies have shown that 
thrombus length and its composition have a strong influence on lysis 
completion time (29, 31). To further validate the computational 
model, future experiments should include measurement and charac-
terization of the initial thrombus properties (e.g., concentrations of 
fibrin and activated platelets, thrombus length, and porosity) before 
thrombolysis so that the experimental conditions can be faithfully re-
produced in the computational simulation.
Figure 8 (A to D) shows variations of the extent of thrombolysis 
(Fig. 8A), fibrin volume fraction (Fig. 8B), fibrin-bound tPA con-
centration (Fig. 8C), and fibrin-bound PLS concentration (Fig. 8D). 
All variables were averaged over the remaining thrombus volume. 
There was virtually no difference between the small and large dense 
thrombi, possibly because both were nonocclusive, allowing fast drug 
delivery by convective flow. An important observation was that tar-
geted thrombolysis by the ND was slow for the small coarse thrombus, 
which was assumed to have a low volume fraction of activated plate-
lets compared to other simulated cases. This was because of the rate 
of tPA release being proportional to the number of activated platelets, 
as demonstrated by the experiment (Fig. 4B) and static simulation 
results (Fig. 6, C and D). These simulation results indicated that tPA- 
cRGD-PEG-NV could be more effective at treating platelet-rich thrombi 
(dense) than platelet-poor thrombi (coarse), although further experi-
ments are needed to confirm this finding.
When free tPA was delivered, the coarse thrombus dissolved 
slightly more rapidly than the dense thrombi due to faster penetra-
tion of tPA, plasminogen, and PLS; the concentration of the result-
ing fibrin-bound PLS for a coarse thrombus was higher than that 
for a dense thrombus. It was also interesting to observe that lysis of 
the dense thrombi by the ND was faster than by free tPA, albeit very 
slightly (up to 5 s). As displayed in Fig. 8 (A and B), the lysis rate was 
slower with the ND than with free tPA in the early phase of throm-
bolysis because of less fibrin-bound tPA (Fig. 8C), possibly due to 
the slower diffusion of the ND and the additional release step com-
pared to free tPA. However, fibrin-bound tPA continued to rise as 
the ND accumulated and released tPA within the thrombus. This led 
to increased levels of fibrin-bound tPA (Fig. 8C) and fibrin-bound 
PLS (Fig. 8D) for the ND-treated thrombi during the later phase, 
thereby accelerating thrombolysis. The simulation results captured 
the experimental data very well in that thrombolysis with tPA-cRGD- 
PEG-NV had a relatively low initial rate of thrombolysis before acceler-
ation (as shown in Fig. 7D and fig. S8C).
Figure 8 (E to G) displays simulation results for the large dense 
thrombi treated with the ND. Local flow velocity and extent of 
thrombolysis at different times are presented in Fig. 8E. Owing to 
the constriction caused by the thrombi and their high resistance to 
flow in the initial phase, there was a high-velocity stream bypassing 
the thrombi through which there was no flow. As fibrin degradation 
progressed, the thrombi became more permeable, allowing flow to 
become more uniformly distributed, as can be seen at 302 s. The 
thrombi did not change their size until the lysis extent reached its 
critical value of 0.95 and then shrank. The disappearance of the entire 
thrombus took only a few seconds in this simulation case because 
the tPA concentration reached its therapeutic level almost uniformly 
over the thrombus volume in the current microfluidics setting 
(movie S5). The same was observed for the simulation of the large 
dense thrombi treated with free tPA (movie S6). These findings 
were in line with the experimental results (movies S3 and S4) where 
thrombus disappearance took place within less than 5 s. Figure 8F 
shows that, inside the thrombus, most tPA was present in a fibrin- 
bound or encapsulated form. A continuous inflow of the ND and 
almost instantaneous binding of free tPA to fibrin resulted in a con-
centration build-up of fibrin-bound tPA. Under a continuous 
infusion mode, the levels of empty ND (CND,empty), INT-bound ND 
(CINT-ND), and INT-bound empty ND (CINT-ND,empty), shown in 
Fig. 8G, reached equilibrium in the early phase of thrombolysis. In 
particular, maintaining a constant level of CINT-ND over time led to 
a continuous increase of ntPA. This implies that less tPA would be 
needed for thrombolytic treatment using tPA-cRGD-PEG-NV than 
in conventional therapy.
In summary, a fibrinogen-mimicking, multiarm nanovesicle, named 
as tPA-cRGD-PEG-NV, was successfully constructed and charac-
terized for effective and selective thrombolysis. The biomimetic 
tPA-cRGD-PEG-NV were small (about 165 nm in diameter) with a 
narrow size distribution and had good stability and negative surface 
charge. CLSM, flow cytometry measurements, and the microfluidics 
study showed highly specific binding of tPA-cRGD-PEG-NV to 
human activated platelets at a thrombus site under both static and 
physiological flow conditions. Efficient tPA release was shown to be 
triggered by human activated platelets through the membrane fusion 
mechanism, and the activated platelet–sensitive tPA release was re-
produced by a purpose-built computational model. The targeted 
thrombolytic activities of tPA-cRGD-PEG-NV and free tPA were 
comparable, resulting in complete removal of human thrombi 
under flow conditions in a microfluidics device in 9.73 ± 0.65 and 
8.34 ± 1.19 min, respectively. In comparison, tPA-PEG-NV without 
cRGD peptide arms led to a decrease in fibrin fluorescence by only 
~20% under the same conditions. Therefore, this fibrinogen-mimicking, 
multiarm nanovesicle holds considerable promise for effective 
and selective thrombolytic therapy with considerably less systemic 
tPA exposure. As demonstrated thus far, the developed computa-
tional model can provide a variety of information to complement 
the experimental work. Although further improvement and rig-
orous validations against well-controlled experiments are needed, the 
current model provides the groundwork for a virtual thrombolysis 
platform that, in the future, may help reduce the number of experi-




tPA (alteplase) was a product of Boehringer Ingelheim (Germany). 
Cholesterol, l--phosphatidylcholine from egg yolk (EPC), cyclo 
(Arg-Gly-Asp-d-Phe-Val) (cRGD), 4-dimethylaminopyridine, 
N-hydroxy succinimide, 1-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide hydrochloride, l--phosphatidylethanolamine-N- 
(7-nitro-2-1,3-benzoxadiazol-4-yl), l--phosphatidylethanolamine- 
N-(lissamine Rhod B sulfonyl), FITC, bovine serum albumin, calcein, 1, 
2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino-
(polyethylene glycol)-2000] (DSPE-PEG-NH2), Dulbecco’s PBS 
(D-PBS), sodium chloride (NaCl), magnesium chloride (MgCl2), 
calcium chloride (CaCl2), Triton X-100, thrombin, plasminogen, 
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fibrinogen, tris(hydroxymethyl) aminomethane, acid citrate dextrose, 
the bicinchoninic acid Protein Assay Kit, and the tPA Chromogenic 
Activity Assay Kit S-2251 were purchased from Sigma-Aldrich 
(Dorset, UK). AF-647-FBG, DiOC6, TF, and centrifugal concentra-
tors were purchased from Thermo Fisher Scientific (Loughborough, 
UK). Chrono-Par collagen was purchased from Labmedics Ltd. 
(Culham Science Centre, UK). Flow chambers Vena8 Fluoro+ BioChips 
(width, 0.04 cm; height, 0.01 cm; length, 2.8 cm) were purchased 
from Cellix Ltd. (Dublin, Ireland). The extruder set, polycarbonate 
membranes, and filter supports were purchased from Avanti Polar 
Lipids Inc. (Alabaster, USA). Chloroform (CHCl3), deuterated 
chloroform (CDCl3), dimethyl sulfoxide (DMSO), deuterated DMSO 
(DMSO-d6), absolute ethyl alcohol, acetone, hydrochloric acid, 
sodium hydroxide, and other chemicals were obtained from VWR 
International Ltd (Lutterworth, UK).
Preparation of fibrinogen-mimicking, multiarm  
lipid nanovesicles
The lipid nanovesicles were prepared via our previously reported 
lipid film hydration method (26). Briefly, EPC and cholesterol at the 
required ratios were dissolved in a binary solvent mixture of 
CHCl3:ethanol = 5:1 (v:v). A lipid film was formed by the removal 
of the organic solvents with rotary evaporation and then hydrated 
with PBS buffer (pH 7.4) at 40°C for 1 hour. The resulting nano-
vesicles were sonicated at 4°C for 30 min and subsequently extruded 
through 200-nm polycarbonate membranes.
To prepare tPA-cRGD-PEG-NV, the cRGD-decorated DSPE-
PEG-cRGD lipid was first synthesized by an amidation reaction be-
tween the free NH2 in DSPE-PEG-NH2 and the free COOH in cRGD 
peptide according to our published protocol (26). Then, a lipid film 
containing EPC, DSPE-PEG-cRGD, and cholesterol was prepared 
following the method as mentioned above and hydrated with PBS 
buffer (pH 7.4) containing tPA at the required concentration. After 
sonication and extrusion, the unencapsulated tPA was removed by 
ultracentrifugation at 4°C. The tPA-loaded lipid nanovesicle with-
out cRGD peptide arms (denoted as tPA-PEG-NV) was synthesized 
for comparison.
Characterization of fibrinogen-mimicking, multiarm  
lipid nanovesicles
The hydrodynamic size, PDI, morphology, and zeta potential of the 
lipid nanovesicles were measured by DLS (Zetasizer Nano S, 
Malvern, UK), TEM (JEOL JEM-2100F, Japan), and zeta potential 
analyzer (ZetaPALS, Brookhaven, USA), respectively.
The NTA of 1 ml of tPA-cRGD-PEG-NV (equivalent tPA con-
centration of 0.314 mg m−1;) in PBS buffer (pH 7.4) was performed 
by a NanoSight NS300 equipped with a 532-nm green laser (Malvern, 
UK). The samples were diluted to an optimum measurement range 
of 1 × 108 to 1 × 109 particles/ml. The measurements were analyzed 
using the Nanosight NTA 3.2 software.
The amounts of tPA encapsulated in the nanovesicle were deter-
mined by the chromogenic substrate S-2251 assay. The encapsula-
tion efficiency (EE) was calculated by the following equation
  %EE =   m l  ─ m t  × 100 (1)
where ml is the weight of encapsulated tPA and mt is the total initial 
weight of tPA in the loading solution.
Preparation of human platelets
All the experiments involving human subjects were permitted by 
and carried out in accordance with the guidelines of the Imperial 
College Research Ethics Committee and Science, Engineering, and 
Technology Research Ethics Committee. Whole human blood was 
collected from healthy volunteers (not taking any medications) in 
acid citrate dextrose [blood/citrate = 9/1 (v/v)]. First, blood was 
centrifuged at 175g for 15 min to prepare platelet-rich plasma, then 
washed twice, and centrifuged at 1400g for 10 min, with 2 M 
prostaglandin E1 as an inhibitor of platelet aggregation. Finally, the 
platelets were resuspended with HT buffer (134 mM NaCl, 2.9 mM 
KCl, 0.34 mM Na2HPO4, 12 mM NaHCO3, 20 mM Hepes, 1 mM 
MgCl2, and 5 mM glucose; pH 7.3) to the desired concentration and 
rested for 30 min before use.
In vitro thrombolysis in a halo human blood clot model
Whole human blood was collected from healthy volunteers (not taking 
any medications) in acid citrate dextrose [blood/citrate = 9/1 (v/v)]. 
A clotting mixture [5 ml of buffer containing 66 mM tris-HCl, 130 mM 
NaCl, 45 mM CaCl2, and 5 l of 1 M thrombin (pH 7.4)] was freshly 
prepared. In a 96-well microplate, one drop of 5 l of clotting mix-
ture was placed on the edge of the well bottom, and then another 
drop of 15 l of whole blood was added on the opposite edge of the 
well bottom. Clotting was initiated by mixing the two drops with a 
pipette tip in a circular motion to form a homogenous halo-shaped 
blood clot around the well edge, leaving the center area empty (39, 46). 
The plate was sealed and incubated at 37°C for 30 min for blood clot 
formation. Eighty microliters of tPA-PEG-NV, tPA-cRGD-PEG-NV, 
or free tPA (equivalent tPA dose of 0.2 mg ml−1) was added into the 
wells containing halo blood clots at the same time. The dissolution 
of halo blood clots was determined by measuring absorbance at 
510 nm with a Sunrise plate reader (Tecan Group Ltd., Switzerland) 
with 5-s orbital shaking, resulting from red blood cells progressively 
covering the center of the well after clot lysis at 37°C. A negative 
control was obtained from the addition of 80 l of PBS only to halo 
thrombi (no tPA), while a well containing 15 l of blood and 85 l 
of PBS (no halo clots) was used as a positive control. The percentage 
of clot dissolution was calculated by the following equation
  %Clot lysis =   A s −  A n  ─ A p −  A n 
  × 100 (2)
where As is the absorbance of the sample well after treatment, An is 
the absorbance of the negative control well, and AP is the absorbance 
of the positive control well. Replicates were obtained with blood 
clots made from the blood of three different donors.
Microfluidics system
Flow chambers with Vena8 Fluoro+ BioChip (width, 0.04 cm; height, 
0.01 cm; and length, 2.8 cm; Cellix Ltd., Ireland) were coated with a 
mixture of fibrillar collagen (50 g ml−1) and TF (50 pM) at 4°C 
overnight. Channels were then blocked at room temperature for 
30 min with 1 weight % bovine serum albumin in HT buffer [134 mM 
NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4, 12 mM NaHCO3, 20 mM 
Hepes, 1 mM MgCl2, and 5 mM glucose (pH 7.3)] and washed with 
HT buffer prior perfusion.
Thrombus selectivity in a microfluidics system
Citrated human blood was perfused in the collagen-coated channels 
at a wall shear rate of 1000 s−1 at room temperature to form nonocclusive 
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thrombi. Then, the channels were washed by perfusion with HT buffer 
for 2 min. FITC-labeled tPA-PEG-NV or tPA-cRGD-PEG-NV were 
perfused in the thrombi-bearing channels for 5 min to demonstrate 
the cRGD-induced selective binding to thrombi. The channels were 
washed by perfusion with HT buffer for 2 min and imaged using a 
Zeiss Axio fluorescence microscope.
Targeted thrombolysis in a microfluidics system
Citrated human blood was preincubated with DIOC6 (2.5 M) and 
AF-647-FBG (300 g ml−1) for 3 min. After that, the blood was mixed 
with CaCl2 (1 mM) and MgCl2 (1 mM) and was then perfused in the 
collagen- and TF-coated channels at a wall shear rate of 1000 s−1 for 
8 min to generate stable nonocclusive thrombi. Images were acquired 
to monitor thrombus formation (platelet and fibrin accumulation). 
Then, channels were washed by perfusion with HT buffer for 2 min, 
and blood containing cRGD-PEG-NV, tPA-PEG-NV, tPA-cRGD-
PEG-NV, or free tPA (equivalent tPA dose of 15 g ml−1) was perfused 
in the channels at a wall shear rate of 1000 s−1 for the indicated time. 
Real-time changes in red fluorescence of fibrin and green fluores-
cence of platelets were monitored. Videos were acquired using a 
Zeiss Axio fluorescence microscope.
Computational modeling
As illustrated in Fig. 1 (D and E), a computational model was developed 
for targeted thrombolysis using our specially designed ND, tPA-
cRGD-PEG-NV. In the model, thrombi were assumed to consist of 
fibrin fiber network and activated platelets, with an initial volume 
fraction of f,0 and p,0, respectively (47). The total initial volume 
fraction of the clot (tot,0) and its void fraction (tot,0) can be 
calculated as
   tot,0 =   f,0 +   p,0 (3)
   tot,0 = 1 −   tot,0 (4)
The volume fraction of activated platelets within a thrombus is 
related to the number of activated platelets, which then determines 
the number of IIb3 INTs expressed on the surface of activated 
platelets
  C PLT,0 =  
 P max   p,0  ─ N AV 
 (5)
  C INT,tot,0 =  N INT  C PLT,0 (6)
where CPLT,0 and CINT,tot,0 are the initial concentration of activated 
platelets and initial total concentration of the IIb3 INTs available 
for ND to bind, respectively. Pmax is the maximum packing density 
for platelets, which was estimated on the basis of the assumption 
that 20 platelets can fit tightly in 300 m3 (48). NAV is Avogadro’s 
number, and NINT is the maximum number of IIb3 INTs expressed 
on the surface of platelets upon activation. Once ND binds with the 
INTs on activated platelets, tPA is released and attaches to fibrin- 
binding sites. The number of fibrin-binding sites was estimated by 
using the fibrin fiber volume fraction f, the mean radius of fibrin 
fibers, and interprotofibril spacing. The initial concentration of 
binding sites, ntot,0, in the fibrin fiber network was calculated using 
the method described in our previous work (29).
The properties of thrombi vary with time due to thrombolytic 
reactions taking place upon the injection of tPA or ND. Multiple 
reactions occur simultaneously in the targeted thrombolytic system, 
which can be categorized into three groups as shown in Fig. 1E: (i) 
fibrinolytic reactions within a blood clot, (ii) plasma reactions, and 
(iii) reactions involving tPA-encapsulated ND. Fibrinolytic reactions 
include bindings between key fibrinolytic proteins—tPA, plasminogen, 
and PLS—and fibrin-binding sites in a clot and degradation of fibrin 
fibers triggered by the bound tPA. The corresponding reaction 
kinetics are described in “Reaction kinetics” section and “Properties 
of blood clots composed of fibrin fiber network and activated plate-
lets” section of the Supplementary Materials based on our previous 
work (29, 30). The third reaction group is specific to the new targeted 
thrombolytic system and needed to be modeled. It was expected 
that ND exhibited highly complex behaviors during its interaction 
with INT. For simplicity, the complex behaviors of ND were de-
scribed by a series of four reactions shown below
  ND + INT  ⇄ 
 k d,ND 
 
 k a,ND 
ND INT (7)
  ND INT   k rel    ⎯ → v rel tPA +  ND empty INT (8)
  ND empty + INT  ⇄  k d,ND 
 
 k a,ND 
 ND empty INT (9)
  ND  
 K lead    ⟷ v rel tPA +  ND empty (10)
where ka,ND and kd,ND are the adsorption and desorption rate con-
stants of ND onto and from the INTs of activated platelets, respec-
tively, krel is the release rate constant, Kleak is the leakage constant, 
and rel is the stochiometric coefficient. The first reversible reaction 
in Eq. 7 represents adsorption and desorption of ND onto and from 
the INT sites available on the surface of activated platelets. INT-
bound ND, NDINT, releases tPA encapsulated in ND via destabiliza-
tion of nanovesicle present in the outermost layer of ND. This is 
described by Eq. 8, where INT-bound ND is converted to tPA and 
INT-bound empty ND without tPA in it, NDempty. We assumed 
that, upon drug release, ND was completely emptied by releasing 
the total amount of encapsulated tPA, withrel representing the 
mole of tPA per mole of ND. Released tPA is either present in sys-
temic plasma or in fibrin-bound phase (where activated platelets 
are embedded), depending on the location of platelets. Also, 
emptied ND can further bind and unbind with INT, as described in 
Eq. 9, which affects the number of free INT-binding sites, CINT,free. 
Furthermore, drug leakage by diffusion was accounted for, as 
shown in Eq. 10.
As ND is transported to the thrombus site and releases tPA, 
thrombolytic reactions take place and the thrombus starts to de-
grade. The extent of lysis EL was used to measure the progression of 
thrombolysis and consequently altered the clot properties. Once the 
extent of lysis reaches its critical value, EL,crit, the thrombus becomes 
completely disintegrated. At the same time, activated platelets lo-
cated in the vicinity of the dissolved binding sites become free and 
return to the plasma phase. All the reactions considered in the cur-
rent computational model are summarized in Fig. 1E.
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Computational simulation of triggered drug release 
and thrombolysis in a static system
Computational simulations mimicking the drug release experiments 
were carried out. Comparing computational and experimental re-
sults allowed us not only to corroborate the proposed mechanism 
for the triggered tPA release but also to estimate reaction kinetics 
parameters for the developed ND system. Thrombolysis in a static 
system, which was assumed to be well mixed, can be mathematically 
described using a system of ordinary differential equations and 
algebraic equations (“Descriptions of reaction model parameters 
and their values” section, “Model equations for flow and species 
transport” section, and “Static conditions” section in the Supple-
mentary Materials). These model equations were numerically solved 
using an inbuilt solver (ode15s) of the variable-order method in 
MATLAB R2019b. For a well-mixed system, the predicted species 
concentrations depended solely on reactions.
Computational simulation of targeted thrombolysis 
in a microfluidics system
Mathematical modeling of the microfluidics system involved a sys-
tem of partial differential equations and algebraic equations. A sim-
ulation platform for the targeted thrombolytic system under flow 
conditions was developed by implementing the model equations 
(“Model equations for flow and species transport” section and 
“Flow simulation” section in the Supplementary Materials) in an 
open-source computational fluid dynamics package, OpenFOAM 
4.0. A three-dimensional rectangular geometry was created to mimic 
the experimental microfluidic system, albeit slightly modified, as 
illustrated in Fig.  1D. Since the exact shape and size of thrombi 
formed inside the microfluidic channels were unknown, three non-
occlusive thrombi were artificially created inside a channel (three 
bumps in the channel, as shown in Fig. 1D). In the microfluidics 
setting, there were continuous inflow and outflow containing mul-
tiple species. Therefore, the transport of species due to convection 
and diffusion must be considered along with the associated reac-
tions. Further computational details and simulation conditions can 
be found in “Supplementary computational simulation details” sec-
tion of the Supplementary Materials.
Statistical analysis
Unless otherwise indicated, the results are presented as average ± SD 
(n ≥ 3) and analyzed using GraphPad Prism (version 6.0). Sta-
tistical analysis was performed using one-way analysis of variance 
(ANOVA) with a Tukey’s post hoc test and Student’s t test. Differ-
ences were considered to be statistically significant when P value 
was <0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/23/eabf9033/DC1
View/request a protocol for this paper from Bio-protocol.
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